Epilepsy - Market Insight, Epidemiology and Market Forecast - 2027

  • ID: 4401825
  • Drug Pipelines
  • Region: Global
  • 127 Pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 3
Covers the Therapeutics Market Revenue, Treatment Practice/Algorithm and Forecasted Market Size of Epilepsy from 2017 to 2025 Segmented by Seven Major Markets
The ‘Epilepsy - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Epilepsy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Epilepsy from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2016-2027

Epilepsy - Disease Understanding and Treatment Algorithm

The Epilepsy market report gives the thorough understanding of the Epilepsy by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Epilepsy in the US, Europe, and Japan.

Epilepsy Epidemiology

The Epilepsy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by sex-specific [Male and Female] and sub-type [Focal/ Partial, Generalized, Unclassified]. The report further covers prevalence of Tuberous Sclerosis Complex (TSC) associated Epilepsy.

According to the report, the prevalent cases of Epilepsy was 7,649,695 in 2016 in 7 MM and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. Among 7MM, United States account for highest prevalent cases of Epilepsy with 4,007,026 prevalent cases in 2016 followed by Germany.

Epilepsy Drug Chapters

This segment of the Epilepsy report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Currently, there are approximately 50 drugs in market for Epilepsy out of which 50% have gone off patent. This report includes detailed chapters of marketed along with the promising upcoming therapies.

Epilepsy Market Outlook

The Epilepsy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Epilepsy market is expected to grow during the forecasted period of 2018-2027 owing to the launch of nine drugs (presently in Phase III). Epilepsy Therapeutics market has seen a global sales of 5.4 billion in 2016. The three best selling drugs were Vimpat (UCB), Lamictal (Glaxosmithkline) and Keppra (UCB) with Vimpat recording highest sales of 895 million in 2016.

Epilepsy Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Epilepsy Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Epilepsy Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Epilepsy Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving the Epilepsy market
  • Organize sales and marketing efforts by identifying the best opportunities for Epilepsy market
  • To understand the future market competition in the Epilepsy market.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Report Summary
2. Epilepsy Disease Background
2.1. Introduction
2.2. Causes
2.3. Symptoms
2.4. Classification
2.5. Risk factors
2.6. Diagnosis
2.7. TSC Mutations in Epilepsy
2.8. Current Treatment & Medical Practices
3. Epidemiology and Patient Population
3.1. Key Points
3.2. United States
3.2.1. Prevalence of Epilepsy in United States
3.2.2. Gender specific prevalence in United States
3.2.3. Sub-type specific prevalence in United States
3.2.4. Prevalence of TSC associated Epilepsy in the United States
3.3. Germany
3.3.1. Prevalence of Epilepsy in Germany
3.3.2. Gender specific prevalence in Germany
3.3.3. Sub-type specific prevalence in Germany
3.3.4. Prevalence of TSC associated Epilepsy in the Germany
3.4. France
3.4.1. Prevalence of Epilepsy in France
3.4.2. Gender specific prevalence in France
3.4.3. Sub-type specific prevalence in France
3.4.4. Prevalence of TSC associated Epilepsy in the France
3.5. Italy
3.5.1. Prevalence of Epilepsy in Italy
3.5.2. Gender specific prevalence in Italy
3.5.3. Sub-type specific prevalence in Italy
3.5.4. Prevalence of TSC associated Epilepsy in the Italy
3.6. Spain
3.6.1. Prevalence of Epilepsy in Spain
3.6.2. Gender specific prevalence in Spain
3.6.3. Sub-type specific prevalence in Spain
3.6.4. Prevalence of TSC associated Epilepsy in the Spain
3.7. United Kingdom
3.7.1. Prevalence of Epilepsy in United Kingdom
3.7.2. Gender specific prevalence in United Kingdom
3.7.3. Sub-type specific prevalence in United Kingdom
3.7.4. Prevalence of TSC associated Epilepsy in the UK
3.8. Japan
3.8.1. Prevalence of Epilepsy in Japan
3.8.2. Gender specific prevalence in Japan
3.8.3. Sub-type specific prevalence in Japan
4. Treatment Algorithm
4.1. NICE Guidelines
4.2. Treatment options in the management of Epilepsy in patients with TSC
4.3. Epilepsy treatment in TSC: Clinical Recommendations
5. Unmet Needs
6. Competitive Landscape-Marketed Drugs
6.1. Vimpat: UCB
6.1.1. Drug Description
6.1.2. Product Profile
6.1.3. Vimpat Sales
6.2. Lyrica: Pfizer
6.2.1. Drug Description
6.2.2. Product Profile
6.2.3. Lyrica Sales
6.3. Banzel: Eisai
6.3.1. Drug Description
6.3.2. Product Profile
6.3.3. Banzel Sales
6.4. Briviact: UCB Pharma
6.4.1. Drug Description
6.4.2. Product Profile
6.4.3. Briviact Sales
6.5. Keppra: UCB
6.5.1. Drug Description
6.5.2. Product Profile
6.5.3. Keppra Sales
6.6. Keppra XR (levetiracetam XR): UCB
6.6.1. Drug Description
6.6.2. Product Profile
6.6.3. Keppra Sales
6.7. Topamax: Janssen
6.7.1. Drug Production
6.7.2. Product Profile
6.7.3. Topamax Sales
6.8. Lamictal: GlaxoSmithKline
6.8.1. Drug Description
6.8.2. Product Profile
6.8.3. Lamictal Sales
6.9. Neurontin: Pfizer
6.9.1. Drug Description
6.9.2. Product Profile
6.9.3. Neurontin Sales
6.10. Zonegran: Eisai
6.10.1. Drug Description
6.10.2. Product Profile
6.10.3. Zonegran Sales
6.11. Trileptal: Novartis
6.11.1. Drug Description
6.11.2. Product Profile
6.11.3. Trileptal Sales
6.12. Zebinix (Aptiom): Dainippon Sumitomo Pharma/Eisai
6.12.1. Drug Description
6.12.2. Product Profile
6.12.3. Zebinix (Aptiom) Sales
6.13. Fycompa: Eisai
6.13.1. Drug Description
6.13.2. Product Profile
6.13.3. Fycompa Sales
7. Emerging Therapies
7.1. Upcoming Drugs
7.2. Epidiolex: GW Pharmaceuticals
7.2.1. Product Description
7.2.2. Research and Development
7.2.3. Product Development Activities
7.3. Fintepla: Zogenix
7.3.1. Product Description
7.3.2. Research and Development
7.3.3. Product Development Activities
7.4. PF-06372865: Pfizer
7.4.1. Product Description
7.4.2. Research & Development
7.5. UCB0942: UCB
7.5.1. Product Description
7.5.2. Research & Development
7.6. Ganaxolone: Marinus Pharmaceuticals
7.6.1. Product Description
7.6.2. Research & Development
7.6.3. Product Development Activities
7.7. SAGE-547: Sage Therapeutics
7.7.1. Product Description
7.7.2. Research and Development
7.7.3. Product Development Activities
7.8. Triheptanoin: Ultragenyx Pharmaceutical
7.8.1. Product Description
7.8.2. Research and Development
7.8.3. Product Development Activities
7.9. CPP-115: Catalyst Pharmaceuticals
7.9.1. Product Description
7.9.2. Research and development
7.9.3. Product Development Activities
7.10. ZYN002: Zynerba Pharma
7.10.1. Product Description
7.10.2. Research and Development
7.10.3. Product Development Activities
8. Market Size of Epilepsy
9. Global Market Size
9.1. Key Findings
9.2. Market Size of Top-10 Products (2016)
9.3. Market Size of Top-10 Products (2025)
9.4. Upcoming Drug Launches-Uptake
10. United States
10.1. Market Outlook of Epilepsy in United States
11. EU5
11.1. Market outlook of Epilepsy in EU5
12. Japan
12.1. Market outlook of Epilepsy in Japan
13. Market Drivers
14. Market Barriers
15. Appendix
15.1. Report Methodology
16. Consulting Services
17. Disclaimer
18. About the Publisher

List of Tables:
Table 1: Prevalent Population of Epilepsy in the United States (2016-2027)
Table 2: Gender specific Prevalent Population of Epilepsy in the United States (2016-2027)
Table 3: Sub-type specific Prevalent Population of Epilepsy in the United States (2016-2027)
Table 4: Prevalence of TSC associated Epilepsy in the United States (2016-2027)
Table 5: Prevalent Population of Epilepsy in the Germany (2016-2027)
Table 6: Gender specific Prevalent Population of Epilepsy in the Germany (2016-2027)
Table 7: Sub-type specific Prevalent Population of Epilepsy in the United States (2016-2027)
Table 8: Prevalence of TSC associated Epilepsy in the Germany (2016-2027)
Table 9: Prevalent Population of Epilepsy in the France (2016-2027)
Table 10: Gender specific Prevalent Population of Epilepsy in the France (2016-2027)
Table 11: Sub-type specific Prevalent Population of Epilepsy in the France (2016-2027)
Table 12: Prevalence of TSC associated Epilepsy in the France (2016-2027)
Table 13: Prevalent Population of Epilepsy in the Italy (2016-2027)
Table 14: Gender specific Prevalent Population of Epilepsy in the Italy (2016-2027)
Table 15: Sub-type specific Prevalent Population of Epilepsy in the Italy (2016-2027)
Table 16: Prevalence of TSC associated Epilepsy in the Italy (2016-2027)
Table 17: Prevalent Population of Epilepsy in the Spain (2016-2027)
Table 18: Gender specific Prevalent Population of Epilepsy in the Spain (2016-2027)
Table 19: Sub-type specific Prevalent Population of Epilepsy in the Spain (2016-2027)
Table 20: Prevalence of TSC associated Epilepsy in the Spain (2016-2027)
Table 21: Prevalent Population of Epilepsy in the United Kingdom (2016-2027)
Table 22: Gender specific Prevalent Population of Epilepsy in the UK (2016-2027)
Table 23: Sub-type specific Prevalent Population of Epilepsy in the UK (2016-2027)
Table 24: Prevalence of TSC associated Epilepsy in the UK (2016-2027)
Table 25: Prevalent Population of Epilepsy in the Japan (2016-2027)
Table 26: Gender specific Prevalent Population of Epilepsy in the Japan (2016-2027)
Table 27: Sub-type specific Prevalent Population of Epilepsy in the Japan (2016-2027)
Table 28: Upcoming therapies and their launch dates (2016-2027)
Table 29: Global Market Size of Epilepsy in USD, Million (2016-2027)
Table 30: Market Size of Top-10 Products (2016)
Table 31: Market Size of Top-10 Products (2025)
Table 32: Upcoming Drug Launches-Uptake Graph (2016-2027)
Table 33: United States Market Size of Epilepsy in USD, Million (2016-2027)
Table 34: EU5 Market Size of Epilepsy in USD, Million (2016-2027)
Table 35:Japan Market Size of Epilepsy in USD, Million (2016-2027)

List of Figures:
Figure 1: ILAE 2017 Classification of Seizure Types Basic Version
Figure 2: ILAE 2017 Classification of Seizure Types Extended Version
Figure 3: Classification of Epilepsy
Figure 4: Prevalent Population of Epilepsy in the United States (2016-2027)
Figure 5: Gender specific Prevalent Population of Epilepsy in the United States (2016-2027)
Figure 6: Sub-type specific Prevalent Population of Epilepsy in the United States (2016-2027)
Figure 7: Prevalence of TSC associated Epilepsy in the United States (2016-2027)
Figure 8: Prevalent Population of Epilepsy in the Germany (2016-2027)
Figure 9: Gender specific Prevalent Population of Epilepsy in the Germany (2016-2027)
Figure 10: Sub-type specific Prevalent Population of Epilepsy in the Germany (2016-2027)
Figure 11: Prevalence of TSC associated Epilepsy in the Germany (2016-2027)
Figure 12: Prevalent Population of Epilepsy in the France (2016-2027)
Figure 13: Gender specific Prevalent Population of Epilepsy in the France (2016-2027)
Figure 14: Sub-type specific Prevalent Population of Epilepsy in the France (2016-2027)
Figure 15: Prevalence of TSC associated Epilepsy in the France (2016-2027)
Figure 16: Prevalent Population of Epilepsy in the Italy (2016-2027)
Figure 17: Gender specific Prevalent Population of Epilepsy in the Italy (2016-2027)
Figure 18: Sub-type specific Prevalent Population of Epilepsy in the Italy (2016-2027)
Figure 19: Prevalence of TSC associated Epilepsy in the Italy (2016-2027)
Figure 20: Prevalent Population of Epilepsy in the Spain (2016-2027)
Figure 21: Gender specific Prevalent Population of Epilepsy in the Spain (2016-2027)
Figure 22: Sub-type specific Prevalent Population of Epilepsy in the Spain (2016-2027)
Figure 23: Prevalence of TSC associated Epilepsy in the Spain (2016-2027)
Figure 24: Prevalent Population of Epilepsy in the United Kingdom (2016-2027)
Figure 25: Gender specific Prevalent Population of Epilepsy in the UK (2016-2027)
Figure 26: Sub-type specific Prevalent Population of Epilepsy in the UK (2016-2027)
Figure 27: Prevalence of TSC associated Epilepsy in the UK (2016-2027)
Figure 28: Prevalent Population of Epilepsy in the Japan (2016-2027)
Figure 29: Gender specific Prevalent Population of Epilepsy in the Japan (2016-2027)
Figure 30: Sub-type specific Prevalent Population of Epilepsy in the Japan (2016-2027)
Figure 31: Seizure-Types and Choice of Anti-Epileptic Drugs (AEDs)
Figure 32: Vimpat: Historical Sales (2012-2016)
Figure 33: Lyrica: Historical Sales (2012-2016)
Figure 34: Banzel: Historical Sales (2012-2016)
Figure 35:: Keppra: Historical Sales (2012-2016)
Figure 36: Keppra: Historical Sales (2012-2016)
Figure 37: Topamax: Historical Sales (2012-2016)
Figure 38:: Lamictal: Historical Sales (2012-2016)
Figure 39: Neurontin: Historical Sales (2012-2016)
Figure 40: Zonegran: Historical Sales (2012-2016)
Figure 41: Trileptal: Historical Sales (2012-2016)
Figure 42: Zebinix: Historical Sales (2012-2016)
Figure 43: Fycompa: Historical Sales (2012-2016)
Figure 44: Global Market size of Epilepsy in USD, Millions (2016-2027)
Figure 45: Market Size of Top-10 Products (2016)
Figure 46: Market Size of Top-10 Products (2025)
Figure 47: Upcoming Drug Launches-Uptake Graph (2016-2027)
Figure 48: United States Market size of Epilepsy in USD, Millions (2016-2027)
Figure 49: EU5 Market size of Epilepsy in USD, Millions (2016-2027)
Figure 50:Japan Market size of Epilepsy in USD, Millions (2016-2027)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll